

CombiGene has been awarded the Horizon 2020 "Seal of Excellence" and 500,000 kronor from Vinnova

The EU research and development programme Horizon 2020, which aims at taking good ideas from the lab to market, has awarded CombiGene a "Seal of Excellence" – a mark of quality for excellent innovations that are promising investments.

In conjunction with the Horizon 2020 "Seal of Excellence", CombiGene has also received 500,000 kronor from Vinnova. The funds will be used to produce a definitive business plan with focus on the company's epilepsy project and which will also address a broader development programme. The business plan will then provide a basis for an application for additional funding via Horizon 2020 to support continued research and development of the epilepsy project.

About CombiGene AB

By combining modern neuroscience with recent advances in gene delivery, CombiGene has developed a method shown to suppress epileptic seizures in preclinical studies. The company's current focus is on developing this treatment method for the benefit of epilepsy patients, but the method can also be potentially developed for use in the treatment of other neurological diseases. CombiGene, which has offices in Medicon Village in Lund, Sweden, was founded on the basis of the results of research conducted at Lund University and the University of Copenhagen. The company is listed on AktieTorget. www.combigene.com.

For further information, please contact:

CombiGene AB (publ)
Jan Nilsson, VD
Tel: +46 (0)704 66 31 63
E-mail: jan.nilsson@combigene.com

CombiGene's newsletter, *Ingeneious*, contains general news and information that is judged not to have a significant effect on the share price. Other issues of *Ingeneious* and press releases are available at www.combigene.com

www.combigene.com

CombiGene AB (publ) Medicon Village, SE-223 81 Lund, Sweden
info@combigene.com